Mohit Bansal, an analyst from Wells Fargo, maintained the Buy rating on Ironwood Pharma (IRWD – Research Report). The associated price target remains the same with $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mohit Bansal’s rating is based on several strategic developments at Ironwood Pharma. The company is enhancing its New Drug Application (NDA) for Apra by including additional data from the STARS Extend study, which could strengthen its clinical profile and support a broad label. This approach, combined with a focused commercialization strategy targeting centers of excellence, is expected to drive early adoption and maintain enteral autonomy in patients.
Additionally, Ironwood Pharma’s timeline for the Apra NDA submission remains on track for the third quarter of 2025, providing ample opportunity to bolster their submission with robust data. Despite ongoing pricing pressures, the company maintains a positive outlook for Linzess, with expectations of high single-digit volume growth. These factors collectively contribute to the Buy rating, reflecting confidence in Ironwood Pharma’s strategic direction and potential for future growth.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $14.00 price target.
IRWD’s price has also changed dramatically for the past six months – from $4.900 to $1.620, which is a -66.94% drop .